Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1157]
News [2523]
Articles [155]
Editorials [8]
Conferences [103]
elearning [18]
Increase in annual cardiorespiratory fitness by 3%+ linked to 35% lower prostate cancer risk
Increase in annual cardiorespiratory fitness by 3%+ linked to 35% lower prostate cancer risk
ASCO GU 2024: Immunotherapy post-surgery improves overall survival for kidney cancer
ASCO GU 2024: Immunotherapy post-surgery improves overall survival for kidney cancer
New study identifies link between presence of oncofoetal ecosystem and liver cancer recurrence
New study identifies link between presence of oncofoetal ecosystem and liver cancer recurrence
Protein identified as a potential biomarker and therapeutic target for aggressive neuroendocrine carcinomas
Protein identified as a potential biomarker and therapeutic target for aggressive neuroendocrine carcinomas
Obesity and alcohol are contributing to increases in bowel cancer rates among young adults
Obesity and alcohol are contributing to increases in bowel cancer rates among young adults
ASCO GU 2024: Subcutaneous nivolumab as effective as IV for renal cell carcinoma with much faster treatment time
ASCO GU 2024: Subcutaneous nivolumab as effective as IV for renal cell carcinoma with much faster treatment time
Researchers discover why one type of chemotherapy works best in bladder cancer
Researchers discover why one type of chemotherapy works best in bladder cancer
ASCO GU 2024: Study shows positive results for patients with muscle-invasive urothelial carcinoma
ASCO GU 2024: Study shows positive results for patients with muscle-invasive urothelial carcinoma
Primary care physicians and urologists work together to provide optimal care for men with low-risk prostate cancer
Primary care physicians and urologists work together to provide optimal care for men with low-risk prostate cancer
ASCO GU 2024: Combination of cabozantinib and atezolizumab offers hope for patients with type of advanced prostate cancer with poor prognosis
ASCO GU 2024: Combination of cabozantinib and atezolizumab offers hope for patients with type of advanced prostate...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation